In this week’s edition of The Prototype, we look at potential first signs of life on another world, an FDA greenlight for ...

Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States against Amgen ...

In this week’s edition of InnovationRx, we look at the impact of Medicaid cuts, a $400 million obesity bet, a study of bias ...

In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S.

In his 13 years as CEO at Amgen, Robert Bradway has seen many of his counterparts at other major biopharma companies come and ...

Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the ...

Originally approved by the FDA in 1998, Amgen’s Enbrel is still sailing along without facing biosimilar competition in the ...

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a ...

Jefferies analyst Michael Yee maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $350.00. The company’s ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

In the latest trading session, Amgen (AMGN) closed at $277.29, marking a -1.89% move from the previous day. This change lagged the S&P 500's 0.13% gain on the day. At the same time, the Dow lost 1.33% ...

Federal Reserve Chairman Jerome Powell said in prepared remarks in Chicago that the central bank would wait for more data ...